ライフサイエンスコーパス: myosin light chain phosphatase

1 vesicle biogenesis through the regulation of myosin light chain phosphatase.

2 h muscle contractility through inhibition of myosin light chain phosphatase.

3 phorylation of the myosin binding subunit of myosin light chain phosphatase.

4 ic activity of myosin light chain kinase and myosin light chain phosphatase.

5 t may be associated with the activation of a myosin light chain phosphatase.

6 o involve a G-protein-mediated inhibition of myosin light chain phosphatase activity by phosphorylati

7 We investigated whether myosin light chain phosphatase activity changes during n

8 cyclic GMP-dependent kinase (cGKI) pathways, myosin light chain phosphatase activity reflects the sum

9 ads to down-regulation of smooth muscle (SM) myosin light chain phosphatase activity, an increase in

10 esensitization in smooth muscle by enhancing myosin light chain phosphatase activity, and cGMP- and/o

11 Ca(2+) sensitivity usually is attributed to myosin light chain phosphatase activity, but findings in

12 the Rho signaling pathway and inhibition of myosin light chain phosphatase activity.

13 n is controlled by MLCK activity relative to myosin light chain phosphatase activity.

14 f MLCK and Rho kinase-mediated inhibition of myosin light chain phosphatase activity.

15 t phosphorylation of LC20 upon inhibition of myosin light chain phosphatase activity.

16 hibitory protein of 17 kDa (CPI-17) inhibits myosin light chain phosphatase, altering the levels of m

17 lated, phosphorylation of the ROCK substrate myosin light chain phosphatase and subsequently, myosin

18 Rho-kinase is known to inhibit myosin light chain phosphatase, and to directly phosphor

19 endogenous MYPT1 (the regulatory subunit of myosin light chain phosphatase) at Thr-696/Thr-853 or ac

20 through RhoA/ROCK-mediated inhibition of the myosin light chain phosphatase complex (MLCP).

21 and/or the leucine zipper (LZ) domain of the myosin light-chain phosphatase component, myosin-binding

22 unts of free Ca(2+)/calmodulin combined with myosin light chain phosphatase inhibition is sufficient

23 This occurs through inhibition of myosin light chain phosphatase, leading to increased pho

24 Inhibition of myosin light chain phosphatase leads to Ca(2+)-independe

25 eral different downstream substrates such as myosin light chain phosphatase, LIM kinase and ezrin/rad

26 Second, p116Rip activated the myosin light chain phosphatase (MLCP) activity of the ho

27 , NO-mediated signals trigger an increase in myosin light chain phosphatase (MLCP) activity.

28 bsequent dephosphorylation for relaxation by myosin light chain phosphatase (MLCP) containing regulat

29 at its N-terminal region, and heterotrimeric myosin light chain phosphatase (MLCP) has been assigned

30 The reversible regulation of myosin light chain phosphatase (MLCP) in response to ago

31 Myosin light chain phosphatase (MLCP) plays a pivotal ro

32 ctivation, force and phosphorylation of RLC, myosin light chain phosphatase (MLCP) targeting subunit

33 We also examined the expression levels of myosin light chain phosphatase (MLCP), the MLCP inhibito

34 ulin-dependent myosin light chain kinase and myosin light chain phosphatase (MLCP), which contains a

35 l of phosphate/mol of RLC with inhibition of myosin light chain phosphatase (MLCP).

36 pendent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP).

37 ed form of myosin-binding subunit (P-MBS) of myosin light chain phosphatase (MLCP).

38 muscle relaxation in part via activation of myosin light chain phosphatase (MLCP).

39 in phosphorylation through the regulation of myosin light chain phosphatase (MLCP).

40 activities of myosin light chain kinase and myosin light chain phosphatase (MLCP).

41 n light chain kinase and dephosphorylated by myosin light chain phosphatase (MLCP).

42 pendent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP).

43 e exhibited an approximately 30% decrease in myosin light-chain phosphatase (MLCP) activity, which wa

44 The small phosphoprotein pCPI-17 inhibits myosin light-chain phosphatase (MLCP).

45 expressed the small subunit of smooth muscle myosin light chain phosphatase (MPs) in Escherichia coli

46 CPI-17, but not myosin targeting subunit of myosin light chain phosphatase (MYPT1).

47 tiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kDa) is phosphoryla

48 lex and allow reevaluation of the role(s) of myosin light-chain phosphatase partner polypeptides in r

49 nist-induced contractile force, RLC(20), and myosin light chain phosphatase phosphorylation in both i

50 Myosin light chain phosphatase plays a critical role in

51 Phosphorylation of two myosin light chain phosphatase regulatory proteins (MYPT

52 Phosphorylation of the myosin light chain phosphatase regulatory subunit MYPT1

53 phosphorylation of myosin light chain or of myosin light chain phosphatase regulatory subunit.

54 cium sensitization reflects an inhibition of myosin light chain phosphatase (SMPP-1m) activity; howev

55 th muscle contraction involves inhibition of myosin light chain phosphatase (SMPP-1M) and enhanced my

56 oA, Rho-kinase-alpha and -beta isoforms, and myosin light chain phosphatase target subunit (MYPT1); h

57 by a GST-MYPT1(654-880) fragment inhibiting myosin light chain phosphatase were antagonized by the a

58 We have characterized the function of myosin light chain phosphatase, which down-regulates myo

59 selectively inhibits a specific form of PP1, myosin light chain phosphatase, which transduces multipl